MON-LB110 A Phase 2 Evaluation of a Ready-To-Use Liquid Stable Continuous Subcutaneous Glucagon Infusion for the Treatment of Hypoglycemia Associated Autonomic Failure

OBJECTIVE:A novel, ready-to-use, liquid stable, continuous subcutaneous glucagon infusion (CSGI; Xeris Pharmaceuticals) was evaluated for the treatment of adults with type 1 diabetes (T1D) with documented Hypoglycemia Associated Autonomic Failure (HAAF). METHOD:This was a Phase 2 prospective, multi-...

Descripción completa

Detalles Bibliográficos
Autores principales: Pettus, Jeremy H, Nakhle, Samer, Ovalle, Fernando, Rickels, Michael Roehrhoff, Umpierrez, Guillermo Enrique, Junaidi, Khaled, Close, Nicole C, Nguyen, Anh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Diabetes Mellitus and Glucose Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208249/
http://dx.doi.org/10.1210/jendso/bvaa046.2331

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208249/
http://dx.doi.org/10.1210/jendso/bvaa046.2331

Ejemplares similares